A 60-year-old man diagnosed with unresectable hepatocellular carcinoma (HCC) presented to the hospital with pain in the perineal region. He had been taking lenvatinib every day for 2 months after he was diagnosed with HCC with metastases to the lymph node, small bowel mesentery, and retroperitoneal space. Enhanced abdominal computed tomography revealed mild elevation in intensity in the perineal subcutaneous tissue with subcutaneous emphysema. The patient was diagnosed with Common Terminology Criteria for Adverse Events grade 3, skin ulceration of stage IV with full-thickness skin loss and tissue necrosis in the muscular layer. The patient was taken off the medication with prescription of antibiotics, and after 3 weeks, the skin has fully recovered. This is the first report of an HCC patient who presented with a skin ulceration of stage IV after lenvatinib treatment. We recommend stopping the medication immediately and changing to alternative treatments with appropriate supportive care.
Citations
Citations to this article as recorded by
Drug-induced skin ulcer: real-world pharmacovigilance analysis based on the FDA adverse event reporting system Qiubai Jin, Jiufei Fang, Feihong Ren, Jiaqi Li, Shuanglin Zhou, Ping Song Expert Opinion on Drug Safety.2026; 25(5): 863. CrossRef
Clinical Management of Adverse Effects Associated with Domestic Lenvatinib in Hepatocellular Carcinoma Patients under Volume-Based Procurement Policy 凯鑫 靳 Asian Case Reports in Emergency Medicine.2026; 14(02): 282. CrossRef
Case Report: Lenvatinib-induced lichenoid drug reaction mimicking disseminated zoster in a patient with metastatic hepatocellular carcinoma Maria Kaufman, Rodrigo Garcia-Santisteban, Crystal Choi, Rohit Merugu, Samuel Kareff Frontiers in Oncology.2026;[Epub] CrossRef
Lenvatinib-Associated Vaginal Necrosis and Rectovaginal Fistula After Brachytherapy Keiichiro Baba, Taisuke Sumiya, Takashi Saito, Motohiro Murakami, Hideyuki Sakurai Cureus.2025;[Epub] CrossRef
Hospital-Based Observational Study of Mucocutaneous Adverse Reactions of Tyrosine Kinase Inhibitors Sona C. Gowda, Tonita Mariola Noronha, Vijith Shetty Indian Journal of Medical and Paediatric Oncology.2025;[Epub] CrossRef
Roles of clinical application of lenvatinib and its resistance mechanism in advanced hepatocellular carcinoma (Review) Ganghui Ye American Journal of Cancer Research.2024; 14(9): 4113. CrossRef
Multiple lenvatinib‐associated skin ulcers: A case report and literature review Soo Hyun Jeon, Woo Jin Lee, Chong Hyun Won, Sung Eun Chang, Mi Woo Lee, Joon Min Jung Australasian Journal of Dermatology.2023;[Epub] CrossRef
Tyrosine Kinase Inhibitors Induced Scrotal Ulcerations Abhipsa Samal, Nibedita Dixit, Bikash R. Kar, Liza Mohapatra Indian Journal of Dermatology.2023; 68(2): 235. CrossRef